PDE4 Inhibitors
8 drugsAbout PDE4
Phosphodiesterase 4 (PDE4) is an intracellular enzyme that hydrolyzes cyclic adenosine monophosphate (cAMP), a second messenger regulating cellular processes. By modulating cAMP levels, PDE4 influences inflammatory and immune responses within cells. This makes it a valuable drug target across several therapeutic areas.
Human genetic studies provide strong validation for PDE4 as a therapeutic target (max score 0.94), with variants linked to 43 diseases. Strong genetic associations include acrodysostosis 2 (score 0.94) and placental retention (score 0.59). These findings support continued development of PDE4-targeting therapies.
PDE4 is targeted by 6 FDA-approved small molecule drugs, including OTEZLA, ROFLUMILAST and ZORYVE. These drugs span respiratory (3 drugs) and immunology (2 drugs) indications. Five companies have approved PDE4-targeting drugs, including Amgen, AstraZeneca, and Arcutis.
PDE4 Genetic Evidence Strong
Genetic evidence strongly supports PDE4 as a drug target, with a maximum score of 0.94.
Strong genetic support suggests a higher probability of clinical success for PDE4-targeting drugs.
Evidence Across Diseases
20 totalGWAS and other genetic studies link PDE4D to 43 diseases.
🔗 Colocalization Evidence 15 strong
max H4: 0.99eQTL/pQTL signals for PDE4D colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top PDE4 Drugs
Five companies have approved PDE4-targeting drugs, with Amgen leading with multiple indications.
The presence of multiple players indicates a competitive market, requiring strong differentiation for new entrants.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| OTEZLA XR | Amgen | 2025 | 3 |
| ZORYVE | ARCUTIS | 2022 | 2 |
| ROFLUMILAST | PHARMAZONE | 2018 | 2 |
| OHTUVAYRE | Merck | 2024 | 1 |
| EUCRISA | ANACOR PHARMS INC | 2016 | 1 |
PDE4 Drug Modality Landscape
Modalities
Routes of Administration
PDE4 is amenable to small molecule drugs, with oral options available for convenient dosing.
The modality landscape suggests an opportunity to explore alternative modalities like antibodies or peptides.
PDE4 Clinical Trials 279 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PDE4. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 38 | 24 | 8 | 6 | 75% |
| Phase 2 | 103 | 65 | 14 | 24 | 82% |
| Phase 3 | 74 | 58 | 3 | 13 | 95% |
| Phase 4 | 64 | 47 | 7 | 10 | 87% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved PDE4 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PDE4. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PDE4 Drug Approval Timeline (1983 - 2025)
The first PDE4-targeting drug was approved in 2011, with the most recent approval in 2025.
The approval timeline indicates continued interest in PDE4 inhibition, but potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 7 companies competing
- • Market share by company
Full Drug Portfolio
- • All 8 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 8-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 141 (32 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PDE4. A trial counts if an approved drug acting on PDE4 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.